Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04765839 · ClinicalTrials.gov registry record · NA

Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations

A NA study of Vaccine Preventable Disease, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
74
Enrollment target
1
Study location

NCT04765839 is a NA study of Vaccine Preventable Disease that has completed, run by Mayo Clinic. The registered enrollment target is 74 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04765839, a NA study of Vaccine Preventable Disease, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants. At baseline, 2 weeks and 4 weeks, the study team will survey participants to assess knowledge and attitudes about COVID-19 vaccines, including intention to be vaccinated.

Interventions

  • OTHER Educational, culturally appropriate COVID-19 messages

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2021-02-12
Est. Completion 2021-04-03
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04765839

The ClinicalTrials.gov registry entry for NCT04765839 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vaccine Preventable Disease appearing as the primary indexed condition, and to 1 intervention - of which Educational, culturally appropriate COVID-19 messages is the first listed.

NCT04765839 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04765839 about?

NCT04765839 is a clinical study titled "Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations". A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants. At baseline, 2 weeks and 4 weeks, the study team will survey participants to assess knowledge and attitudes ...

What is the current status of trial NCT04765839?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2021-02-12. Estimated completion is 2021-04-03.

What conditions does trial NCT04765839 study?

This clinical trial studies the following conditions: Vaccine Preventable Disease.

What interventions are being tested in trial NCT04765839?

The interventions under investigation include: Educational, culturally appropriate COVID-19 messages (OTHER).

Who is sponsoring clinical trial NCT04765839?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04765839 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.